Vote Scores

Home / Companies / CRISPR THERAPEUTICS AG / 4 Jun 2026

Meeting · year to 30 June 2026625 filers reporting

CRISPR THERAPEUTICS AG: meeting of 4 Jun 2026

Votes reported on Form N-PX, item by item

625 Form N-PX filers reported votes at the CRISPR THERAPEUTICS AG meeting of 4 Jun 2026. Their records fall into 7 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

12 nominees; 76.6% of reported votes for; 89 filers withheld from or voted against at least one nominee.

3,235 vote records from 117 filers. 14 of the 109 filers that marked the item either way voted against management. 8 filers reported this item without a management mark.

80.3% for12.8% against6.8% other12.8% against management117 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

1,343 vote records from 622 filers. 264 of the 575 filers that marked the item either way voted against management. 47 filers reported this item without a management mark.

46.8% for42.9% against10.3% other45.9% against management622 filers70.1% for29.5% against0.4% other29.1% against management64,283,935 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

243 vote records from 115 filers. 1 of the 107 filers that marked the item either way voted against management. 8 filers reported this item without a management mark.

92.2% for0.0% against7.8% other0.9% against management115 filers99.9% for0.0% against0.1% other0.1% against management19,702,646 reported shares
4

CAPITAL STRUCTUREIssuer

CAPITAL STRUCTURE: management items

Management items in this category are shown together; filers word and number them differently.

667 vote records from 115 filers. 0 of the 107 filers that marked the item either way voted against management. 8 filers reported this item without a management mark.

93.0% for0.0% against7.0% other0.0% against management115 filers99.5% for0.5% against0.5% against management58,091,227 reported shares, counted once per item in this group
5

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

1,641 vote records from 124 filers. 35 of the 114 filers that marked the item either way voted against management. 10 filers reported this item without a management mark.

62.1% for30.6% against7.3% other30.7% against management124 filers92.1% for7.9% against0.0% other7.8% against management137,395,032 reported shares, counted once per item in this group
6

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

1,189 vote records from 116 filers. 3 of the 108 filers that marked the item either way voted against management. 8 filers reported this item without a management mark.

90.5% for2.6% against6.9% other2.8% against management116 filers93.0% for7.0% against6.9% against management105,088,697 reported shares, counted once per item in this group
7

OTHERIssuer

OTHER: management items

Management items in this category are shown together; filers word and number them differently.

65 vote records from 19 filers. 0 of the 18 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

52.6% for0.0% against47.4% other0.0% against management19 filers99.3% for0.7% against0.7% against management20,340,046 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesForForFor
FidelityForAgainst *For
DimensionalAgainst *Against *For
State Street and SPDRForForFor
American CenturyForForFor
Franklin TempletonForAgainst *For
InvescoForAgainst *For
EquitableAgainst *Against *For
Charles SchwabForAgainst *For
Nuveen and TIAAForAgainst *For
ProShares and ProFundsForAgainst *For
John Hancock and ManulifeForAgainst *For
Morgan Stanley, Eaton Vance and CalvertForAgainst *For
J.P. MorganAgainst *ForFor
Goldman SachsForAgainst *For
WisdomTreeForForFor
PGIM and PrudentialForAgainst *For
Jackson National fundsForForFor
Northern Trust and FlexSharesForAgainst *For
SEIForAgainst *For
T. Rowe PriceForForFor
Lincoln FinancialAgainst *ForFor
VoyaForForFor
First TrustNo reportAgainst *No report
Russell InvestmentsForAgainst *For
NationwideAgainst *Against *For
Brighthouse FundsAgainstForFor
Guggenheim and RydexForAgainst *For
Columbia ThreadneedleForAgainst *For
BNY MellonNo reportForNo report
PrincipalSplit or no voteSplit or no voteSplit or no vote
Capital Group and American FundsForAgainst *For
Pacific Life fundsForForFor
Global XForAgainst *For
Federated HermesNo reportAgainst *No report
AllianceBernsteinNo reportAgainst *No report
DWSForAgainst *For
PIMCOForAgainst *For
AllspringForAgainst *For
MassMutualForForFor
Neuberger BermanNo reportAgainst *No report
American BeaconForForFor
Natixis and Loomis SaylesAgainst *Against *For
Lord AbbettNo reportForNo report
BairdNo reportAgainst *No report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the CRISPR THERAPEUTICS AG meeting?

625 Form N-PX filers reported votes at the meeting of 4 Jun 2026. On say-on-pay, 264 of 575 voted against management (45.9%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by CRISPR THERAPEUTICS AG on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for CRISPR THERAPEUTICS AG

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing CRISPR THERAPEUTICS AG with a meeting date within three days of 4 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.